Trial Profile
A Single Site, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira in Healthy 'Adults' aged >18 to <60 years and in Healthy 'Older Adults' aged >60 years for the 2006/2007 Northern Hemisphere Influenza Season.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Aug 2019
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Afluria) (Primary) ; Influenza virus vaccine (Afluria) (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors CSL
- 02 Aug 2019 Status changed from recruiting to completed.
- 01 Jun 2011 New trial record